Data / Drug companies / Biogen Inc.
Biogen Inc.: 52 products in the FDA NDC directory, labeler code 64406
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Biogen Inc. (labeler code 64406) lists 52 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 22 prescription drugs, 16 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on March 27, 2026.
The request: Watch Biogen Inc. (FDA labeler code 64406): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 64406
- Products in commercial distribution
- 52
- Packages
- 56
- Finished drugs by generic name
- 10
- Prescription products
- 22
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 3
- Flagged as original packager
- 12 of 12 products that carry the flag
- Started marketing in the last 12 months
- 2
- Products with a marketing end date set
- 4
- Earliest marketing start
- May 23, 2003
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 16 | 30.8% |
| Bulk ingredients | 14 | 26.9% |
| New drug applications (NDA) | 12 | 23.1% |
| Biologics (BLA) | 10 | 19.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 22 | 42.3% |
| Drugs for further processing | 16 | 30.8% |
| Bulk ingredients | 14 | 26.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Peginterferon beta-1a | 5 | 1 |
| Dimethyl fumarate | 3 | 20 |
| Zuranolone | 3 | 1 |
| Nusinersen | 3 | 1 |
| Tocilizumab | 3 | 4 |
| Diroximel fumarate | 1 | 1 |
| Natalizumab | 1 | 1 |
| Tofersen | 1 | 1 |
| Ranibizumab-nuna | 1 | 2 |
| Omaveloxolone | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Liquid | 16 | 30.8% |
| Injection, solution | 9 | 17.3% |
| Capsule | 7 | 13.5% |
| Powder, for suspension | 6 | 11.5% |
| Powder, for solution | 6 | 11.5% |
| Injection | 5 | 9.6% |
| Kit | 3 | 5.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Antisense Oligonucleotide | 4 |
| Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator | 3 |
| Survival Motor Neuron-2-directed RNA Interaction | 3 |
| Interferon beta | 3 |
| Interleukin-6 Receptor Antagonist | 3 |
| Integrin Receptor Antagonist | 1 |
| Vascular Endothelial Growth Factor Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Spinraza | 64406-037 | Injection, solution | New drug applications (NDA) | March 27, 2026 |
| Spinraza | 64406-036 | Injection, solution | New drug applications (NDA) | March 27, 2026 |
| Nusinersen | 64406-311 | Injection, solution | Drugs for further processing | May 18, 2025 |
| Nusinersen | 64406-310 | Injection, solution | Drugs for further processing | May 18, 2025 |
| Tofidence | 64406-024 | Injection | Biologics (BLA) | May 1, 2024 |
| Tofidence | 64406-023 | Injection | Biologics (BLA) | May 1, 2024 |
| Tofidence | 64406-022 | Injection | Biologics (BLA) | May 1, 2024 |
| Zurzuvae | 64406-031 | Capsule | New drug applications (NDA) | October 31, 2023 |
| Zurzuvae | 64406-030 | Capsule | New drug applications (NDA) | October 31, 2023 |
| Zurzuvae | 64406-029 | Capsule | New drug applications (NDA) | October 31, 2023 |
| Talquetamab | 64406-540 | Liquid | Bulk ingredients | August 9, 2023 |
| Qalsody | 64406-109 | Injection | New drug applications (NDA) | April 25, 2023 |
| Skyclarys | 64406-250 | Capsule | New drug applications (NDA) | February 28, 2023 |
| Efanesoctocog alfa | 64406-715 | Powder, for solution | Drugs for further processing | February 22, 2023 |
| Efanesoctocog alfa | 64406-714 | Powder, for solution | Drugs for further processing | February 22, 2023 |
| Efanesoctocog alfa | 64406-713 | Powder, for solution | Drugs for further processing | February 22, 2023 |
| Efanesoctocog alfa | 64406-712 | Powder, for solution | Drugs for further processing | February 22, 2023 |
| Efanesoctocog alfa | 64406-711 | Powder, for solution | Drugs for further processing | February 22, 2023 |
| Efanesoctocog alfa | 64406-710 | Powder, for solution | Drugs for further processing | February 22, 2023 |
| Efanesoctocog alfa | 64406-530 | Liquid | Bulk ingredients | February 22, 2023 |
| Lecanemab | 64406-330 | Liquid | Drugs for further processing | January 6, 2023 |
| Lecanemab | 64406-200 | Liquid | Bulk ingredients | December 16, 2022 |
| Teclistamab | 64406-580 | Liquid | Bulk ingredients | October 25, 2022 |
| Byooviz | 64406-019 | Injection, solution | Biologics (BLA) | June 1, 2022 |
| Sutimlimab | 64406-510 | Liquid | Bulk ingredients | February 4, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.